Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

3.95
+0.930030.79%
Post-market: 4.470.5203+13.17%18:50 EST
Volume:74.57M
Turnover:272.35M
Market Cap:3.89B
PE:-9.51
High:3.99
Open:3.14
Low:3.07
Close:3.02
52wk High:4.27
52wk Low:1.83
Shares:984.97M
Float Shares:194.00M
Volume Ratio:3.23
T/O Rate:38.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4153
EPS(LYR):-0.5931
ROE:78.05%
ROA:-36.89%
PB:-7.42
PE(LYR):-6.66

Loading ...

ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug

Benzinga
·
6 hours ago

ImmunityBio rises 22.2%

TIPRANKS
·
6 hours ago

ImmunityBio Currently Up 10 Straight Days, on Pace for Record Winning Streak -- Data Talk

Dow Jones
·
6 hours ago

Immunitybio Shares Hit Highest Since June, Last up 12.6% After Co's Prelim Quarterly Revenue Exceeds Estimates

THOMSON REUTERS
·
Yesterday

Immunitybio Inc - for Three-Month Period Ending Dec 31, 2025 Sees $38.3 Mln Prelim Net Product Revenue

THOMSON REUTERS
·
Yesterday

ImmunityBio Reports Preliminary 2025 Net Product Revenue of $113 Million

Reuters
·
Yesterday

ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment

Dow Jones
·
Yesterday

Saudi FDA grants accelerated approval to ImmunityBio’s ANKTIVA for NSCLC

TIPRANKS
·
Jan 14

Saudi FDA Approves ImmunityBio’s ANKTIVA for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Reuters
·
Jan 14

Saudi FDA Grants Accelerated Approval to Immunitybio’s Anktiva® in Combination With Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Jan 14

Immunitybio Inc: Anktiva Bla Submission Targeted by Year-End

THOMSON REUTERS
·
Jan 14

Saudi FDA Grants Accelerated Approval to Immunitybio’s Anktiva® for Non-Muscle Invasive Bladder Cancer With Carcinoma in-Situ

THOMSON REUTERS
·
Jan 14

Immunitybio- Enrollment in Randomized Trial of Anktiva in Bcg NaÏVe Nmibc Patients Ahead of Schedule With Full Enrollment Anticipated by Q2 2026

THOMSON REUTERS
·
Jan 14

ImmunityBio Shares Rise on Positive Results From Lung Cancer Drug Trials

Dow Jones
·
Jan 14

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 14

ImmunityBio Reports Positive ANKTIVA Trial Results in Non-Small Cell Lung Cancer

Reuters
·
Jan 13

Immunitybio Announces Positive Results Demonstrating Anktiva® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Jan 13

Immunitybio Inc - Responders With Anktiva Plus CPI Have Longer Survival

THOMSON REUTERS
·
Jan 13

Immunitybio Inc - Anktiva Plus CPI Shows Significant Immune Restoration in Nsclc

THOMSON REUTERS
·
Jan 13

Immunitybio Inc - Phase 3 Trial Comparing Anktiva Plus CPI Versus Docetaxel Ongoing

THOMSON REUTERS
·
Jan 13